import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "peptide-half-life-comparison-reference-2026",
  title: "Peptide Half-Life Comparison: A Reference Guide for Researchers",
  description:
    "A comprehensive reference comparing half-lives, active windows, and dosing frequency implications for the most commonly researched peptides — GH secretagogues, tissue repair, longevity, and GLP-1 class compounds.",
  category: "Research Fundamentals",
  readMinutes: 9,
  publishedAt: "2026-06-19",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Half-life is one of the most practically important pharmacokinetic parameters in research protocol design. A peptide's half-life determines how frequently it must be administered to maintain biologically relevant concentrations, shapes the timing of experimental endpoints, and influences the interpretation of dose-response relationships. Yet half-life data for many research peptides is scattered across preclinical literature and often presented only in the context of specific animal models.",
    },
    {
      type: "paragraph",
      text: "This reference compiles published and estimated half-life data for commonly researched peptides, organized by compound class, with notes on the mechanisms that drive half-life differences.",
    },
    {
      type: "heading",
      text: "Why Peptide Half-Lives Are Generally Short",
    },
    {
      type: "paragraph",
      text: "Most unmodified peptides have short plasma half-lives — often measured in minutes to a few hours. The primary mechanisms of peptide clearance include:",
    },
    {
      type: "list",
      items: [
        "Proteolytic degradation: peptidases and proteases in plasma, kidney, liver, and the target tissue itself cleave peptide bonds",
        "Renal filtration: small peptides (under ~60 kDa) pass through the glomerular filtration barrier and are degraded in the proximal tubules",
        "Receptor-mediated internalization: peptide-receptor complexes are sometimes internalized and the peptide degraded intracellularly",
        "Hepatic first-pass metabolism: relevant for peptides administered by non-parenteral routes",
      ],
    },
    {
      type: "paragraph",
      text: "Pharmaceutical modifications extend half-life by reducing susceptibility to these clearance mechanisms. Key strategies include: PEGylation (polyethylene glycol conjugation), fatty acid conjugation for albumin binding (used in semaglutide), DAC (Drug Affinity Complex) albumin-binding technology (used in CJC-1295 with DAC), and incorporation of D-amino acids to resist protease degradation.",
    },
    {
      type: "heading",
      text: "GH Axis Peptides: Half-Life Reference",
    },
    {
      type: "table",
      headers: ["Compound", "Approximate Half-Life", "Primary Clearance Mechanism", "Dosing Implication"],
      rows: [
        ["Ipamorelin", "~2 hours (rat)", "Proteolytic degradation", "Multiple daily administrations in research"],
        ["GHRP-2 (Pralmorelin)", "~30 min (plasma)", "Rapid proteolytic degradation", "High-frequency dosing; acute pulse studies"],
        ["GHRP-6", "~15–30 min (plasma)", "Rapid degradation", "Acute stimulation studies; very high frequency"],
        ["Hexarelin", "~30 min (active window)", "Rapid clearance; note receptor desensitization", "Cycling protocols required to prevent tachyphylaxis"],
        ["CJC-1295 (no DAC)", "~30 min (GHRH-like)", "Dipeptidyl peptidase IV (DPP-IV) cleavage", "Mimics endogenous GHRH pulsatility"],
        ["CJC-1295 (with DAC)", "~6–8 days (albumin binding)", "Slow albumin dissociation + gradual clearance", "Once or twice weekly administration"],
        ["Sermorelin", "~10–20 min", "DPP-IV cleavage at N-terminal", "Short half-life drives interest in more stable analogs"],
        ["MK-677 (Ibutamoren)*", "~5–6 hours (oral bioavailable)", "Hepatic metabolism", "Once daily oral; not technically a peptide"],
      ],
    },
    {
      type: "paragraph",
      text: "*MK-677 is a non-peptide GH secretagogue but is frequently researched alongside GH axis peptides.",
    },
    {
      type: "heading",
      text: "Tissue Repair Peptides: Half-Life Reference",
    },
    {
      type: "table",
      headers: ["Compound", "Approximate Half-Life", "Notes"],
      rows: [
        ["BPC-157", "Variable; hours estimated", "Limited formal half-life studies; oral stability higher than most peptides due to resistance to gastric acidic degradation"],
        ["TB-500 (Thymosin β4)", "Estimated hours to days", "Actin-sequestering protein; intracellular distribution complicates plasma half-life measurement"],
        ["GHK-Cu", "Very short in plasma", "Tripeptide rapidly degraded; local tissue effects likely driven by depot kinetics at administration site"],
        ["LL-37", "Minutes in plasma", "Host defense peptide; rapidly inactivated by serum proteins"],
        ["KPV", "Very short (tripeptide)", "Tripeptide; used in gut research often via local delivery rather than systemic"],
      ],
    },
    {
      type: "heading",
      text: "Longevity and Mitochondrial Peptides",
    },
    {
      type: "table",
      headers: ["Compound", "Approximate Half-Life", "Notes"],
      rows: [
        ["Epithalon (Epitalon)", "Estimated minutes-hours", "Tetrapeptide; formal half-life data limited; Khavinson group publications focus on functional effects over extended protocols"],
        ["MOTS-c", "Estimated hours (mouse)", "Mitochondria-derived peptide; circulating levels detectable for hours after SC administration"],
        ["Humanin", "Estimated hours", "Similar MDP profile to MOTS-c; both show dose-dependent decline over hours"],
        ["SS-31 (Elamipretide)", "~2–4 hours (rat)", "Mitochondria-targeted; accumulates in inner mitochondrial membrane"],
        ["Thymosin Alpha-1", "~2 hours (SC administration)", "Well-characterized in clinical pharmacokinetic studies from Zadaxin trials"],
      ],
    },
    {
      type: "heading",
      text: "GLP-1 Class: Half-Life Reference",
    },
    {
      type: "paragraph",
      text: "GLP-1 receptor agonists are among the most pharmacokinetically engineered peptides in research. Endogenous GLP-1 has a half-life of only ~2 minutes due to rapid DPP-IV cleavage; the entire pharmaceutical development effort focused on extending this to enable practical therapeutic use.",
    },
    {
      type: "table",
      headers: ["Compound", "Half-Life", "Extension Mechanism", "Dosing"],
      rows: [
        ["Endogenous GLP-1", "~2 minutes", "None; rapidly degraded by DPP-IV", "Not applicable"],
        ["Exenatide (Exendin-4)", "~2.4 hours", "DPP-IV resistance; Gila monster origin sequence", "Twice daily SC in clinical use"],
        ["Liraglutide", "~13 hours", "C16 fatty acid chain → albumin binding", "Once daily SC"],
        ["Semaglutide", "~7 days", "C18 fatty acid diacid → albumin binding; backbone modification", "Once weekly SC or oral"],
        ["Tirzepatide", "~5 days", "GIP/GLP-1 dual agonist; C20 fatty acid → albumin binding", "Once weekly SC"],
        ["Retatrutide", "~6 days (estimated)", "GIP/GLP-1/glucagon triple agonist; similar conjugation", "Once weekly SC"],
      ],
    },
    {
      type: "heading",
      text: "Nootropic and Neuropeptides",
    },
    {
      type: "table",
      headers: ["Compound", "Approximate Half-Life", "Notes"],
      rows: [
        ["Semax (ACTH 4-7 Pro-Gly-Pro)", "~20 min (intranasal to CNS)", "N-terminal acetylation extends half-life; N-Acetyl Semax Amidate further extends"],
        ["N-Acetyl Semax Amidate", "Estimated 2–4× longer than Semax", "C-terminal amidation and N-acetylation each contribute resistance to exopeptidases"],
        ["Selank (Tuftsin analog)", "~20 min (estimated)", "Analog modifications extend vs. native tuftsin; intranasal delivery preferred"],
        ["Cerebrolysin", "Very short (peptide mixture)", "Complex brain peptide hydrolysate; short systemic half-life; CNS effects via BDNF-like signaling"],
        ["DSIP (Delta Sleep-Inducing Peptide)", "~30–60 min (estimated)", "Nonapeptide with rapid CNS clearance"],
      ],
    },
    {
      type: "heading",
      text: "Reproductive Axis Peptides",
    },
    {
      type: "table",
      headers: ["Compound", "Approximate Half-Life", "Notes"],
      rows: [
        ["Kisspeptin-10", "~27 min (IV in humans, clinical data)", "Short; rapid renal clearance and proteolysis"],
        ["Kisspeptin-54", "~28 min (IV in humans, clinical data)", "Marginally longer than K-10 despite larger size"],
        ["Triptorelin (GnRH agonist)", "~7–8 hours (SC)", "Synthetic GnRH analog with extended half-life vs. endogenous GnRH (2–4 min)"],
        ["Oxytocin", "~3–20 min (plasma)", "Rapid degradation by oxytocinase; intranasal delivery for CNS research bypasses systemic clearance"],
      ],
    },
    {
      type: "heading",
      text: "Implications for Research Protocol Design",
    },
    {
      type: "subheading",
      text: "Frequency of Administration",
    },
    {
      type: "paragraph",
      text: "For peptides with half-lives of minutes to 2 hours (GHRP-2, GHK-Cu, most unmodified peptides), maintaining continuous systemic exposure requires multiple daily administrations or continuous infusion. Most preclinical protocols with these compounds administer 1–3× daily. For compounds with DAC technology or fatty acid conjugation (CJC-1295 w/DAC, Semaglutide), much less frequent dosing maintains relevant exposures.",
    },
    {
      type: "subheading",
      text: "Pulsatility vs. Sustained Exposure",
    },
    {
      type: "paragraph",
      text: "For GH axis research, pulsatility matters. Endogenous GH is released in pulses, and GH receptor responses are sensitive to pulse pattern. Short-acting GH secretagogues (Ipamorelin, GHRP-2) better mimic this pulsatility than long-acting variants. Research questions about whether GH pulsatility per se drives downstream effects — versus sustained GH elevation — specifically require compounds with different half-life profiles.",
    },
    {
      type: "subheading",
      text: "Receptor Desensitization",
    },
    {
      type: "paragraph",
      text: "Compounds that produce sustained receptor activation may drive receptor downregulation. Hexarelin, for example, shows more pronounced desensitization than Ipamorelin in repeat-dosing paradigms — driving interest in cycling protocols. Understanding half-life helps anticipate which compounds are likely to produce tachyphylaxis in extended studies.",
    },
    {
      type: "subheading",
      text: "Study Endpoint Timing",
    },
    {
      type: "paragraph",
      text: "Biomarker measurements (IGF-1 after GH secretagogue administration, for example) should be timed relative to expected peak plasma concentrations and GH pulse timing. Measuring IGF-1 immediately after peptide administration vs. 12–24 hours later produces very different results. Half-life data anchors appropriate endpoint timing.",
    },
    {
      type: "heading",
      text: "A Note on Data Quality",
    },
    {
      type: "paragraph",
      text: "Half-life data for many research peptides is limited, poorly characterized, or derived only from specific animal models. Human pharmacokinetic data exists for approved clinical compounds (GLP-1 agonists, Thymosin Alpha-1, Kisspeptin in trials) but not for most research-only peptides. Rodent-derived half-life estimates should not be directly applied to human contexts. This reference is intended as a starting point for protocol design, not definitive pharmacokinetic authority.",
    },
    {
      type: "disclaimer",
      text: "For research purposes only. Not intended for human use. Half-life values are approximate and sourced from available preclinical and clinical literature; individual values may vary by model organism, route of administration, and formulation.",
    },
  ],
};
